Key Highlights

  • Defiance Daily Target 2X Long Hims &Amp; Hers ETF (Nasdaq: HIMZ) rose 12.92%, reflecting amplified exposure to Hims & Hers Health (NYSE: HIMS).
  • Canaccord Genuity reiterated a Buy rating on Hims & Hers Health (NYSE: HIMS) with a $32 price target, citing peptide-related growth optionality.
  • Hims & Hers Health (NYSE: HIMS) has invested in peptide Manufacturing, diagnostics and in-house testing capabilities.
  • The company is seeking to reduce reliance on GLP-1 weight-loss drugs by expanding into preventive care, longevity, hormone health and AI-enabled healthcare tools.
  • Regulatory clarity around compounded peptides remains a key Factor for the company’s long-term positioning.

HIMZ ETF Gains as Leveraged Exposure Magnifies HIMS Stock Move

Defiance Daily Target 2X Long Hims & Hers ETF (NASDAQ: HIMZ) is gaining 12.92% today as investor attention returns to Hims & Hers Health (NYSE: HIMS), the digital health company that underpins the ETF’s daily leveraged strategy.

The ETF is designed to provide two times the daily performance of Hims & Hers Health (NYSE: HIMS), meaning short-term moves in the underlying stock can be magnified. That structure helps explain why Defiance Daily Target 2X Long Hims & Hers ETF (NASDAQ: HIMZ) can move sharply when sentiment around Hims & Hers Health (NYSE: HIMS) improves.

The latest rise comes as Wall Street focuses on the company’s potential expansion into peptides, a category linked to preventive health, longevity, metabolic support and broader wellness services.

Canaccord Reiterates Positive View on Hims & Hers Health

Canaccord Genuity reiterated its rating on Hims & Hers Health (NYSE: HIMS), maintaining a $32 price target and pointing to peptides as a possible Long-term Growth driver. The brokerage’s view centres on the company’s transition from a telehealth platform focused on consumer access to a more vertically integrated healthcare Business.

The firm highlighted the US Food and Drug Administration’s review of several compounded peptide substances as a potential inflection point for the market. Regulatory clarity could shift Demand away from less formal or unregulated channels and into mainstream healthcare providers with manufacturing, diagnostics and clinical infrastructure.

For Hims & Hers Health (NYSE: HIMS), that distinction is important. The company has spent the past year expanding its healthcare stack beyond online consultations and prescription fulfilment.

Peptide Manufacturing Adds Strategic Optionality

Hims & Hers Health (NYSE: HIMS) acquired a California-based peptide manufacturing Facility in 2025, strengthening its domestic Supply chain and giving the company greater control over production capacity. It later added in-house lab testing capabilities, which could support a wider range of diagnostic-led services.

These moves suggest management is attempting to build a more defensible operating model. In digital health, customer Acquisition alone is rarely enough to sustain margins. Companies with integrated diagnostics, fulfilment, clinical workflows and manufacturing capacity may be better placed to manage quality control, pricing and regulatory compliance.

The peptide opportunity also fits into a broader shift in consumer healthcare. Demand is increasingly moving toward personalised wellness, longevity, metabolic health and preventive care. Hims & Hers Health (NYSE: HIMS) is attempting to position itself across these areas rather than remain dependent on a single product cycle.

HIMS Diversifies Beyond GLP-1 Weight-Loss Drugs

The market has closely linked Hims & Hers Health (NYSE: HIMS) to GLP-1 weight-loss treatments. While that category has provided a major growth narrative, it also carries regulatory, supply and competitive risks. The company’s expansion into peptides, diagnostics, hormone health and AI-powered healthcare tools is therefore material for investors assessing Revenue durability.

Hims & Hers Health (NYSE: HIMS) has also completed its acquisition of Eucalyptus, a digital health platform with operations across the US, UK, Canada, Australia and other international markets. Eucalyptus has served more than 850,000 customers, adding scale and geographic breadth to Hims’ platform.

The company has stated long-term targets of $6.5bn in revenue and $1.3bn in adjusted EBITDA by 2030. Those figures provide context for why investors are watching the company’s Diversification strategy closely, although execution risk remains significant.

Regulatory and Execution Risks Remain Central

The rally in Defiance Daily Target 2X Long Hims & Hers ETF (NASDAQ: HIMZ) reflects optimism around Hims & Hers Health (NYSE: HIMS), but the underlying Investment case remains sensitive to several variables.

The FDA’s review of compounded peptide substances could shape the size and accessibility of the market. Any restrictive outcome may limit near-term commercial opportunities. Conversely, clearer standards could favour companies with stronger infrastructure and compliance systems.

Competition is another factor. Preventive care, longevity and weight management are attracting healthcare platforms, pharmacies, diagnostics companies and consumer wellness brands. Hims & Hers Health (NYSE: HIMS) will need to show that its vertical integration can translate into sustainable customer retention and operating Leverage.

For Defiance Daily Target 2X Long Hims & Hers ETF (NASDAQ: HIMZ), the risk profile is more pronounced. Leveraged single-stock ETFs are designed for daily exposure and can diverge materially from longer-term stock performance because of compounding and Volatility.